# Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

> **NCT01264211** · PHASE2 · COMPLETED · sponsor: **TRB Chemedica** · enrollment: 40 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Diacerein
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01264211
- **Lead sponsor:** TRB Chemedica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-06
- **Final completion:** 2014-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01264211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01264211, "Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01264211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*